International Clinical Trial: A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816237) titled 'A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy' on Sept. 4.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd.

Condition: Paroxysmal Nocturnal Hemoglobinuria, PNH

Intervention: Drug: VSA012

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enr...